AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16823248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg/day for the first 2 days, then 25 mg/day for 90 days)
Number of subjects: 77
Study 16823248 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/day for 90 days)
Number of subjects: 77
Study 16823248 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (2 mg/day for 90 days)
Number of subjects: 77
Study 12764341 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 40
Study 12764341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 40
Study 10799347 — intervention group
Group type: COMPARATOR
Intervention: 500 mg valerian and 120 mg hops (low dosage)
Number of subjects: 12
Study 10799347 — intervention group
Group type: COMPARATOR
Intervention: 1500 mg valerian and 360 mg hops (high dosage)
Number of subjects: 12
Study 9404921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (busulfan 16 mg/kg, etoposide 40 mg/kg, cytosine arabinoside 3 g/m2 x 4) followed by autologous peripheral blood stem cell transplantation (ABSCT) in 13 patients.
Number of subjects: 60
Study 9404921 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administered concurrently with the BEA regimen during conditioning in 47 patients.
Number of subjects: 60
Study 9404921 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (patients in relapse).
Number of subjects: 60
Study 9404921 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified).
Number of subjects: 60
Study 8362632 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1000 mg/day for 10 days) in Group A
Number of subjects: 62
Study 8362632 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg/day for 10 days) in Group B
Number of subjects: 62
Study 8362632 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (1 g/day for 14 days) in Group C
Number of subjects: 62
Study 3750135 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 micrograms postoperatively
Number of subjects: 61
Study 3750135 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine 1.5 mg/kg 4‐6‐hourly as required
Number of subjects: 61
Study 30092092 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal training (balance and fine hand exercises)
Number of subjects: 21
Study 30092092 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (weight‐supported robotic‐assisted)
Number of subjects: 21
Study 27363518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (750 g/week)
Number of subjects: 38
Study 27363518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (750 g/week)
Number of subjects: 38
Study 27363518 — intervention group
Group type: COMPARATOR
Intervention: Lean meat (control)
Number of subjects: 38
Study 24886338 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's maneuver
Number of subjects: 49400
Study 24886338 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 49400
Study 23045213 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for 7 days or less (n = 188)
Number of subjects: 377
Study 23045213 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue RBCs (n = 189)
Number of subjects: 377
Study 20229000 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg(‐1) (small-dose group, n = 12)
Number of subjects: 24
Study 20229000 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.3 mg kg(‐1) (large-dose group, n = 12)
Number of subjects: 24
Study 20229000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of midazolam (0.2 and 0.3 mg kg(‐1))
Number of subjects: 24
Study 18520802 — intervention group
Group type: EXPERIMENTAL
Intervention: PPX/carboplatin (PPX 210 mg/m/10 min without routine steroid premedication)
Number of subjects: 400
Study 18520802 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin (Paclitaxel 225 mg/m/3 h with standard premedication)
Number of subjects: 400
Study 18520802 — intervention group
Group type: EXPERIMENTAL
Intervention: PPX/carboplatin
Number of subjects: 400
Study 18520802 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin
Number of subjects: 400
Study 15249792 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with higher sodium intake (142 mmol/d)
Number of subjects: 100
Study 15249792 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with lower sodium intake (65 mmol/d)
Number of subjects: 100
Study 15249792 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet with higher sodium intake (142 mmol/d)
Number of subjects: 100
Study 15249792 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet with lower sodium intake (65 mmol/d)
Number of subjects: 100
Study 15249792 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet with intermediate sodium intake (107 mmol/d)
Number of subjects: 100
Study 11733659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.4 minimum alveolar concentration)
Number of subjects: 0
Study 11733659 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.4 minimum alveolar concentration)
Number of subjects: 0
Study 11733659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 11733659 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 9310093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 130
Study 9310093 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized balance training (BT)
Number of subjects: 130
Study 9310093 — intervention group
Group type: COMPARATOR
Intervention: Exercise control education (ED)
Number of subjects: 130
Study 8393685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg/day)
Number of subjects: 15
Study 8393685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3526617 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinfar administered sublingually at a dose of 10-30 mg
Number of subjects: 0
Study 31262371 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFA daily for 3 months
Number of subjects: 70
Study 31262371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31262371 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFA daily for 3 months (after washout)
Number of subjects: 70
Study 31262371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after washout)
Number of subjects: 70
Study 29141712 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART (C-ART)
Number of subjects: 632
Study 29141712 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ART interruptions (2/4-ART)
Number of subjects: 632
Study 29141712 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-guided ART interruptions (CD4GT)
Number of subjects: 632
Study 29141712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial infections
Number of subjects: 632
Study 29141712 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HIV-related morbidity
Number of subjects: 632
Study 27337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental inspiratory threshold loading
Number of subjects: 15
Study 27337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexor loading
Number of subjects: 15
Study 24686130 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 60
Study 24686130 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice (UDA)
Number of subjects: 60
Study 22523305 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass grafting
Number of subjects: 900
Study 22523305 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 900
Study 22523305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900
Study 19232601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) alone
Number of subjects: 32
Study 19232601 — intervention group
Group type: EXPERIMENTAL
Intervention: PFME combined with biofeedback
Number of subjects: 32
Study 19232601 — intervention group
Group type: EXPERIMENTAL
Intervention: PFME combined with electrical stimulation
Number of subjects: 32
Study 17890476 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol (200 microg)
Number of subjects: 60
Study 17890476 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide (40 microg)
Number of subjects: 60
Study 17890476 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 15372589 — intervention group
Group type: EXPERIMENTAL
Intervention: entacapone 200 mg
Number of subjects: 0
Study 15372589 — intervention group
Group type: EXPERIMENTAL
Intervention: entacapone 400 mg
Number of subjects: 0
Study 15372589 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 15372589 — intervention group
Group type: EXPERIMENTAL
Intervention: entacapone (200 mg and 400 mg)
Number of subjects: 0
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam core build-ups (Duralloy, Degussa Ltd, Cheshire, UK)
Number of subjects: 10
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid composite material
Number of subjects: 10
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cermet material (Ketac-Silver, ESPE GmbH, Seefeld, Germany)
Number of subjects: 10
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-composite materials (prisma APH, Ti-Core, Coradent)
Number of subjects: 10
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Core build-ups (all materials) after crown preparation
Number of subjects: 10
Study 11203847 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam core build-ups after crown preparation
Number of subjects: 10
Study 9347122 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 13
Study 9347122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8442592 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2)
Number of subjects: 14
Study 8442592 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study 3510594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold potassium cardioplegia with St. Thomas' Hospital solution (Group 1)
Number of subjects: 30
Study 3510594 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ischemic arrest (Group 2)
Number of subjects: 30
Study 3510594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold potassium cardioplegia (Group 1)
Number of subjects: 30
Study 31006007 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (EPA and DHA) at doses reflecting 1, 2, or 4 portions of oily fish per week (3.27 g EPA + DHA per portion)
Number of subjects: 121
Study 31006007 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (EPA and DHA)
Number of subjects: 121
Study 29664955 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanically-based yoga exercise (YE)
Number of subjects: 31
Study 29664955 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional exercise (TE)
Number of subjects: 31
Study 29664955 — intervention group
Group type: COMPARATOR
Intervention: No-exercise attention-equivalent control (NE)
Number of subjects: 31
Study 28671082 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuang medicine medicated thread moxibustion
Number of subjects: 60
Study 28671082 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment group
Number of subjects: 60
Study 26180248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet pudding
Number of subjects: 20
Study 26180248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter pudding
Number of subjects: 20
Study 26180248 — intervention group
Group type: COMPARATOR
Intervention: Control pudding
Number of subjects: 20
Study 24012033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin
Number of subjects: 910
Study 24012033 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 910
Study 21127284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg levobupivacaine + 10 μg fentanyl
Number of subjects: 90
Study 21127284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg levobupivacaine + 10 μg fentanyl
Number of subjects: 90
Study 21127284 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg levobupivacaine + 10 μg fentanyl
Number of subjects: 90
Study 19068600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach osteotomy, iliac bone graft and internal fixation (Group A)
Number of subjects: 34
Study 19068600 — intervention group
Group type: COMPARATOR
Intervention: Transpedicular posterior decompression and internal fixation (Group B)
Number of subjects: 34
Study 16820547 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily, n = 344)
Number of subjects: 1027
Study 16820547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily, n = 342)
Number of subjects: 1027
Study 16820547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 341)
Number of subjects: 1027
Study 12715635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive type II diabetes mellitus
Number of subjects: 30
Study 12715635 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive type II diabetes mellitus
Number of subjects: 30
Study 12715635 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 30
Study 10886201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous vitamin K
Number of subjects: 24
Study 10886201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous vitamin K
Number of subjects: 24
Study 10886201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous vitamin K
Number of subjects: 24
Study 10886201 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 9039339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen replacement therapy (17 beta-oestradiol 2 mg daily on days 1-22 and 1 mg daily on days 23-28, norethisterone 1 mg days 13-22)
Number of subjects: 14
Study 9039339 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestrogen replacement therapy (oestradiol 50 micrograms/24 h on days 1-28, norethisterone 250 micrograms/24 h on days 15-28)
Number of subjects: 14
Study 1554119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 10% lidocaine gel with 3% glycyrrhetinic acid monohemiphthalate disodium (GAMHPh)
Number of subjects: 24
Study 1554119 — intervention group
Group type: COMPARATOR
Intervention: Control group (Transdermal 10% lidocaine gel without GAMHPh)
Number of subjects: 24
Study 30883268 — intervention group
Group type: EXPERIMENTAL
Intervention: Online patient simulation (OPS) in addition to training as usual (TAU)
Number of subjects: 308
Study 30883268 — intervention group
Group type: COMPARATOR
Intervention: Training as usual (TAU)
Number of subjects: 308
Study 27246516 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme combining multimodal exercises with psychologist‐lead cognitive‐behavioural therapy sessions
Number of subjects: 170
Study 27246516 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (control group)
Number of subjects: 170
Study 25676529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (with prestudy heparin)
Number of subjects: 8281
Study 25676529 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA (with prestudy heparin)
Number of subjects: 8281
Study 25676529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (without prestudy heparin)
Number of subjects: 8281
Study 25676529 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA (without prestudy heparin)
Number of subjects: 8281
Study 24405575 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Management in Licensed Environments intervention delivered by Environmental Health Officers
Number of subjects: 0
Study 24405575 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22871683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision-based tracking
Number of subjects: 44
Study 22871683 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptics
Number of subjects: 44
Study 22871683 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exoskeleton
Number of subjects: 44
Study 19251798 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotitrating bilevel ventilator (AutoVPAP)
Number of subjects: 20
Study 19251798 — intervention group
Group type: COMPARATOR
Intervention: Standard bilevel ventilator (VPAP III)
Number of subjects: 20
Study 17999429 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐B (20 U, 100 U, or 500 U/0.2 mL)
Number of subjects: 48
Study 17999429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16206608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (i.v. prospidin 200‐300 mg/week + i.m. methotrexate 10 mg/week)
Number of subjects: 63
Study 16206608 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (10 mg/week i.m.)
Number of subjects: 63
Study 16206608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 63
Study 16206608 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 63
Study 11881901 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright orientation
Number of subjects: 24
Study 11881901 — intervention group
Group type: COMPARATOR
Intervention: Inverted orientation
Number of subjects: 24
Study 9924157 — intervention group
Group type: EXPERIMENTAL
Intervention: Video telecommunication network for transmitting coronary images during procedures
Number of subjects: 40
Study 7477994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisone (20 mg daily for the first week and 10 mg daily for the second week)
Number of subjects: 0
Study 7477994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2142574 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene and ethinyl estradiol (Femovan)
Number of subjects: 69
Study 2142574 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel and ethinyl estradiol (Marvelon)
Number of subjects: 69
Study 2142574 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ethinyl estradiol from Femovan
Number of subjects: 69
Study 2142574 — intervention group
Group type: COMPARATOR
Intervention: Single-dose ethinyl estradiol from Marvelon
Number of subjects: 69
Study 7421154 — intervention group
Group type: EXPERIMENTAL
Intervention: SPICAs (short versions of the Porch Index of Communicative Ability)
Number of subjects: 93
Study 7421154 — intervention group
Group type: COMPARATOR
Intervention: Standard PICA
Number of subjects: 93
Study 29508532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular self-management support program (5A's self-management support program)
Number of subjects: 12
Study 29508532 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 12
Study 28414857 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) before term
Number of subjects: 1765
Study 28414857 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) before term with anterior placenta
Number of subjects: 1765
Study 25872503 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text-based smoking cessation intervention
Number of subjects: 0
Study 25872503 — intervention group
Group type: COMPARATOR
Intervention: Delayed/waiting list intervention control condition
Number of subjects: 0
Study 23512951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (diet, exercise, weight loss)
Number of subjects: 3819
Study 23512951 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3819
Study 23512951 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 3819
Study 20619408 — intervention group
Group type: EXPERIMENTAL
Intervention: Early standard enteral nutrition (EN) provided within 24 hours of injury
Number of subjects: 126
Study 19678952 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg human AAT (Prolastin) weekly infusions
Number of subjects: 77
Study 19678952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 17367973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (5, 20, 45 s)
Number of subjects: 128
Study 17367973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (10, 25, 50 s)
Number of subjects: 128
Study 17367973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (15, 30, 55 s)
Number of subjects: 128
Study 17367973 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection protocol used in this study
Number of subjects: 128
Study 15311314 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 12
Study 15311314 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and 250 mg of metronidazole (3 times a day for 10 days)
Number of subjects: 12
Study 15311314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 12
Study 11333061 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform shocks (first shock 150 J, second shock 150 J if necessary)
Number of subjects: 57
Study 11333061 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform shocks (first shock 150 J, second shock 360 J if necessary)
Number of subjects: 57
Study 11333061 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform shocks
Number of subjects: 57
Study 11333061 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform shocks
Number of subjects: 57
Study 9765722 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (lumpectomy with axillary dissection)
Number of subjects: 7
Study 9765722 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 7
Study 7524997 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TURP
Number of subjects: 167
Study 7524997 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TURP
Number of subjects: 167